MedTrace Logo

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

NCT03740529 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 803

Last updated 2026-01-27

No results posted yet for this study

Summary

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

Conditions

Interventions

DRUG

Pirtobrutinib

Oral

DRUG

Venetoclax

Oral

DRUG

Rituximab

IV

Sponsors & Collaborators

Principal Investigators

  • Donald Tsai, MD, PhD · Loxo Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-15
Primary Completion
2025-01-27
Completion
2025-12-23
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Italy
  • Japan
  • Poland
  • South Korea
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03740529 on ClinicalTrials.gov